EGFR and neoplasm: Despite not being previously studied in NSCLC, SBS18 has been associated with tumor metastasis and worse prognosis in breast and prostate cancer [112, 113] and it has been strongly linked with sensitivity to EGFR inhibition to afatinib [114].